ARMP

#3613
Armata Pharmaceuticals, Inc. Common Stock
5.3 7 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
5.37
5.57
Intervallo Annuale
3.49
14.90
Variazione giornaliera
-3.59%
Variazione Mensile
+5.29%
Variazione di 6 mesi
-50.82%
Variazione Annuale
-34.29%
Chiusura Precedente
5.5 7
Open
5.5 7
Minimo
5.3 7
Massimo
5.5 7
Volume
3
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Armata Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Armata Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Armata Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Armata Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Armata Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Armata Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Armata Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Armata Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Armata Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Armata Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Armata Pharmaceuticals, Inc. current report, Q2 FY2024

Full document

Armata Pharmaceuticals, Inc. - 8-K Summary

Business Context and Reporting Period

This Form 8-K Current Report covers the Annual Meeting of Shareholders held on June 12, 2024. The filing details the results of shareholder votes regarding board elections, executive compensation, and the ratification of the independent auditor.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.

Material Changes and Voting Results

Shareholders approved the following matters at the Annual Meeting:

  • Board of Directors Election: Seven directors were elected for one-year terms expiring in 2025. All candidates received significant support, with "For" votes ranging from approximately 29.4 million to 30.1 million shares. Broker non-votes totaled 1,351,031 shares for each director.
  • Executive Compensation: Shareholders approved the compensation of named executive officers on a non-binding advisory basis. The vote was 30,142,693 shares for, 55,393 against, and 18,285 abstaining.
  • Auditor Ratification: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The vote was 31,543,360 shares for, 20,716 against, and 3,326 abstaining.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder meeting.

Investor Verification Checklist

  • Verify the composition of the newly elected Board of Directors and their respective terms.
  • Confirm the appointment of Ernst & Young LLP as the independent auditor for the 2024 fiscal year.
  • Review the specific executive compensation plan details referenced in the non-binding advisory vote.
  • Check subsequent filings (e.g., 10-K or 10-Q) for the financial metrics absent in this 8-K.

Notizie